Login to Your Account



Thrombogenics gets $76M cash boost as Novartis exits Jetrea deal

By Cormac Sheridan
Staff Writer

Monday, September 18, 2017

DUBLIN – Shares in Thrombogenics NV rose 16 percent Monday on news that the Alcon unit of Novartis AG was handing back ex-U.S. rights to Jetrea (ocriplasmin), while also providing a cash payment of €53.7 million (US$64.2 million) and an equity investment of €10 million to the Leuven, Belgium-based biotech.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription